Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Adam23 encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Additionally we are shipping Adam23 Proteins (4) and Adam23 Kits (3) and many more products for this protein.
Showing 10 out of 74 products:
Human Polyclonal Adam23 Primary Antibody for EIA, WB - ABIN950268
Pan, Yang, Wei, Sun, Li: SP1 acts as a key factor, contributes to upregulation of ADAM23 expression under serum deprivation. in Biochemical and biophysical research communications 2010
Show all 5 references for 950268
Human Polyclonal Adam23 Primary Antibody for IHC, IHC (p) - ABIN4278231
Costa, Barnabé, Li, Dias, Machado, Asprino, Cavalher, Ferreira, Del Mar Inda, Nagai, Malnic, Duarte, Leite, de Barros, Carraro, Chammas, Armelin, Cavenee, Furnari, Camargo: Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. in Oncogene 2015
ADAM23 expression on DCs partially governs antigen-presentation capacities to responder CD4 (show CD4 Antibodies)(+) T cells. Knockdown did not alter the maturation profile of DCs but impaired cognate T cell responses, decreased antigen-specific clonal expansion, and decreased Th cytokine production. Targeting the alpha(v)beta(3) integrin receptors resulted in similar phenotypes indicating their role in the ADAM23 response.
Interaction proteomics revealed the interactors of Caspr2 (show CNTNAP2 Antibodies), including CNTN2 (show CNTN2 Antibodies), KCNAs, members of the ADAM family (ADAM22 (show ADAM22 Antibodies), ADAM23 and ADAM11 (show ADAM11 Antibodies)), members of LGI family and MAGUKs (DLGs and MPPs (show MPHOSPH6 Antibodies)).
Adam23 knockdown up-regulates P27KIP1 (show CDKN1B Antibodies) in P19 (show CDKN2D Antibodies)/ADAM23 knockdown cells, one reason that P19 (show CDKN2D Antibodies)/ADAM23 knockdown cells can differentiate into neurons without retinoic acid induction.
Data suggest that leucine-rich glioma inactivated 3 (LGI3 (show LGI3 Antibodies)) may be a candidate adipokine that is perturbed in obesity and suppresses adipogenesis through its receptor, ADAM23.
Data suggest that LGI1 (show LGI1 Antibodies) binding to ADAM23 is necessary to correctly pattern neuronal morphology, and altered anatomical patterning contributes to autosomal dominant partial epilepsy with auditory features.
These results suggest ADAM23 may play roles in both early and later stage of neuronal differentiation.
PrP(C (show PRNP Antibodies)) is a novel molecular partner for ADAM23 in the nervous systems.
Functional role of ADAM23 during lung cancer metastatic progression by negatively modulating alpha(v)beta(3) integrin activation.
these results support the existence of a second mechanism, alternative to inhibition of protein secretion, by which ADLTE (show LGI1 Antibodies)-causing LGI1 (show LGI1 Antibodies) mutations exert their loss-of-function effect extracellularly, and suggest that interactions of LGI1 (show LGI1 Antibodies) with both ADAM22 (show ADAM22 Antibodies) and ADAM23 play an important role in the molecular mechanisms leading to utosomal dominant lateral temporal epilepsy
Our data provide evidence that ADAM23 plays a role in suppression of cancer cell progression through interaction with aVb3 integrin, and suggest that downregulation of ADAM23 in SP cells may contribute toward providing a cancer stem cell phenotype
High ADAM23 gene methylation is associated with gastric tumor aggressiveness.
quantification of CXCL12 (show CXCL12 Antibodies) and ADAM23 methylation could be useful for the prediction of advanced stage of BC
Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 (show LGI4 Antibodies) and nitric oxide signals.
The expression level of ADAM23 is likely to be involved in the progression of non-small-cell lung carcinoma, and its downregulation is probably correlated with promoter methylation.
a SP1 (show PSG1 Antibodies) binding site (-202/-190) that binds SP1 (show PSG1 Antibodies) at the proximal promoter of human ADAM23 gene was indentified.
Together, these results indicate that ADAM23 down-regulation by methylation in brain tumors is a rare event and it may help explain why brain tumor metastases are rarely found elsewhere in the body.
ADAM23 is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter methylation.
ADAM23 may be down-regulated by aberrant promoter hypermethylation during the progression of colorectal cancer.
This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. This gene is highly expressed in the brain and may function as an integrin ligand in the brain.
, a disintegrin and metalloprotease domain 23
, disintegrin and metalloproteinase domain-containing protein 23
, metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3
, a disintegrin and metallopeptidase domain 23